Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Als entities : Hepion pharmaceuticals, inc. save search
Hepion Pharmaceuticals to Present at the Q1 Investor Summit Conference
Published: 2022-03-07 (Crawled : 13:00) - hepionpharma.com
HEPA | $2.18 -0.46% -2.1% 9.9K
|
Health Technology
|
| O: 1.24%
H: 0.0%
C: 0.0%
als conference
Hepion Pharmaceuticals Appoints World-Renowned Hepatologist, Dr. Eddie C. Cheung, to Lead the Company’s Strategic Medical Affairs in Asia
Published: 2022-02-15 (Crawled : 13:00) - hepionpharma.com
HEPA | $2.18 -0.46% -2.1% 9.9K
|
Health Technology
|
| O: 1.0%
H: 5.94%
C: 0.99%
als air
Hepion Pharmaceuticals to Present at BIO CEO & Investor Conference
Published: 2022-02-14 (Crawled : 13:00) - hepionpharma.com
HEPA | $2.18 -0.46% -2.1% 9.9K
|
Health Technology
|
| O: -0.96%
H: 0.97%
C: -2.91%
als ceo conference
Hepion Pharmaceuticals’ Rencofilstat, in Combination with an Immune Checkpoint Inhibitor, Demonstrates Synergistic Anti-Tumor Activity in a Nonclinical Liver Cancer Study
Published: 2022-01-26 (Crawled : 13:00) - hepionpharma.com
HEPA | $2.18 -0.46% -2.1% 9.9K
|
Health Technology
|
| O: 2.0%
H: 2.45%
C: -4.42%
als liver cancer
Hepion Pharmaceuticals Announces USAN Selection of “Rencofilstat” as Nonproprietary Name for CRV431
Published: 2022-01-06 (Crawled : 22:00) - contravir.com
HEPA | $2.18 -0.46% -2.1% 9.9K
|
Health Technology
|
| O: 2.46%
H: 1.63%
C: 0.82%
crv431 als ces
Hepion Pharmaceuticals Announces Participation in the H.C. Wainwright BioConnect Conference
Published: 2022-01-05 (Crawled : 10:00) - contravir.com
HEPA | $2.18 -0.46% -2.1% 9.9K
|
Health Technology
|
| O: -1.64%
H: 2.5%
C: 0.83%
als ces conference
Hepion Pharmaceuticals to Present Clinical Data at NASH-TAG Conference
Published: 2022-01-05 (Crawled : 13:30) - hepionpharma.com
HEPA | $2.18 -0.46% -2.1% 9.9K
|
Health Technology
|
| O: 0.81%
H: 2.4%
C: -2.4%
als conference nash
Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liver Cancer
Published: 2021-12-21 (Crawled : 13:00) - hepionpharma.com
HEPA | $2.18 -0.46% -2.1% 9.9K
|
Health Technology
|
| O: 0.83%
H: 7.38%
C: 0.82%
crv431 treatment fda als clearance application liver fda clearance cancer
Gainers vs Losers
| 45% | 55% |
Top 10 Gainers
KAVL | $6.3 135.96% 57.45% 44M
|
Wholesale Trade
PXMD | $0.74 79.7% 44.16% 4.5M
|
Health Technology
DYNT | $0.3704 -5.27% 43.09% 5.5M
|
Health Technology
LGVN P 3 d | $2.93 73.37% 42.52% 56M
|
HUBC | $1.95 50.0% 32.99% 73M
|
n/a
SPCB | $0.4004 45.07% 31.75% 130M
|
Electronic Technology
ONVO | $1.35 33.65% 24.62% 53M
|
Health Technology
OMQS | $0.7038 35.35% 24.3% 3.5M
|
Professional, Scientific, and T...
SNPO | $10.54 29.48% 22.88% 3.9M
|
SNGX | $0.47 21.73% 17.38% 130M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.